ANTI-BK VIRUS ANTIBODY MOLECULES

Abstract

Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.

Claims

1. (canceled)

2. An anti-BK virus antibody molecule or binding fragment thereof comprising: a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 21, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 22, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 23; and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 24, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 25, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 26.

3. The antibody molecule or binding fragment thereof of claim 2 comprising: (i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 27, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 27, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 28, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 28; or (ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 27, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 27, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 31, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 31.

4. The antibody molecule or binding fragment thereof of claim 2 comprising (i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 27, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 28; or (ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 27, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 31.

5. The antibody molecule or binding fragment thereof of claim 2 comprising one or more of the following properties: (i) binds to BK virus serotype I VP1 with an EC50 of less than about 10 nM when the antibody molecule or binding fragment thereof is tested as a bivalent molecule using an ELISA assay; (ii) binds to BK virus serotype II VP1 with an EC50 of less than about 10 nM when the antibody molecule or binding fragment thereof is tested as a bivalent molecule using an ELISA assay; (iii) binds to BK virus serotype III VP1 with an EC50 of less than about 10 nM when the antibody molecule or binding fragment thereof is tested as a bivalent molecule using an ELISA assay; (v) does not bind to JC virus VP1; (vi) neutralizes BK virus serotype I; (vii) neutralizes BK virus serotype II; (viii) neutralizes BK virus serotype III; or (ix) neutralizes BK virus serotype IV.

6. (canceled)

7. A pharmaceutical composition comprising the antibody molecule or binding fragment thereof of claim 2 and a pharmaceutically acceptable carrier, excipient or stabilizer.

8. A method of treating a BK virus infection and/or a BK virus associated disorder, the method comprising administering to a subject in need thereof an antibody molecule or binding fragment thereof according to claim 2.

9. A nucleic acid encoding the heavy and/or light chain variable region of the antibody molecule or binding fragment thereof of claim 2.

10. An expression vector comprising the nucleic acid of claim 9.

11. A host cell comprising the nucleic acid of claim 9.

12. A method of producing an antibody molecule, the method comprising culturing the host cell of claim 11 under conditions suitable for gene expression.

13. A diagnostic composition comprising the antibody molecule or binding fragment thereof of claim 2.

14. A method of treating a BK virus infection and/or a BK virus associated disorder, the method comprising administering to a subject in need thereof a pharmaceutical composition according to claim 7.

15. A host cell comprising the expression vector of claim 10.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0140] FIG. 1. Binding of anti-BK virus antibodies to BKV-VP1 serotypes I-IV in ELISA. These Data were used to determine the EC50.sub.E values by three-parameter analysis in GraphPad Prism Software.

[0141] FIG. 2. Quantitative assessment of antibody-mediated neutralization of BKV strains (serotype Ia, Ib, II, III and IV). 293TT cells were used as target for infection by luciferase expressing BK-pseudovirus formed with either serotype Ia, Ib, II, III and IV VP1. Anti-BK virus antibodies were used in the indicated concentrations.

[0142] FIG. 3. Long-term virus neutralization of wild type BKV on human primary renal tubular epithelial cells by anti-BK virus antibodies. Residual virus load after long term co-incubation of cells, BK virus and anti-BK virus antibodies at the indicated concentrations is indicated. Antibody concentrations correspond to EC 95 (1.500), EC50 (0.15) and EC5 (0.015). P8D11 is labelled with “BM2” in this figure.

[0143] FIG. 4. Binding of anti-BK virus antibodies to a conformational epitope.

[0144] FIG. 5. Assessment of binding strength in ELISA to VP1-mutants and JCV-of antibody 319C07 and antibody 336F07 compared to antibody P8D11. EC50 values to the various mutant forms of VP1 and JC-VP1 were determined in comparison to wild type VP1. VP1 mutants are designated in standard format where the number refers to position in the VP1-STI sequence that was changed from the amino acid left from the number to the amino acid right of the number.

[0145] The graphs show binding of antibody 319C07, antibody 336F07, isotype control antibody 24C03 and antibody P8D11 with a selection of BKV-VP1 mutants and JCV-VP1 and as irrelevant antigen CMV-gH pentamers.

[0146] The table shows data for all BKV-VP1 mutants tested and JCV-VP1. “+” is used to designate that no difference in binding affinity observed between original sequence and mutated sequence. “red” designates a reduced binding “−” designates that no binding was observed.

[0147] FIG. 6. Inhibition of BKV spread on HRPTEC by anti-BK virus antibodies (P8D11 is labelled with “BM2” in this figure).

[0148] FIG. 7. ADCC activity of anti-BKV antibodies on infected and non-infected HPRTEC.

[0149] FIG. 8. CDC activity of anti-BKV antibodies on infected and non-infected HPRTEC in the presence of human serum.

DETAILED DESCRIPTION

[0150] The present invention as illustratively described in the following may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein.

[0151] The present invention will be described with respect to particular embodiments and with reference to certain figures but the invention is not limited thereto but only by the claims.

[0152] Where the term “comprising” is used in the present description and claims, it does not exclude other elements. For the purposes of the present invention, the term “consisting of” is considered to be a preferred embodiment of the term “comprising of”. If hereinafter a group is defined to comprise at least a certain number of embodiments, this is also to be understood to disclose a group, which preferably consists only of these embodiments.

[0153] Where an indefinite or definite article is used when referring to a singular noun, e.g. “a”, “an” or “the”, this includes a plural of that noun unless something else is specifically stated. The terms “about” or “approximately” in the context of the present invention denote an interval of accuracy that the person skilled in the art will understand to still ensure the technical effect of the feature in question. The term indicates deviation from the indicated numerical value of ±20%, preferably ±10%, and more preferably of ±5%.

[0154] Technical terms are used in their common meaning. If a specific meaning is conveyed to certain terms, definitions of terms will be given in the following in the context of which the terms are used.

[0155] Certain aspects of the present disclosure are based, at least in part, on the identification of anti-BK virus antibody molecules or binding fragments thereof that [0156] bind to and neutralize BK virus serotype I; and/or [0157] bind to and neutralize neutralizes BK virus serotype II; and/or [0158] bind to and neutralize neutralizes BK virus serotype III; and/or [0159] bind to and neutralize neutralizes BK virus serotype IV; and/or [0160] do not bind to JC virus VP1.

[0161] In a preferred embodiment, the anti-BK virus antibody molecules or binding fragments thereof neutralize BK virus serotypes I, II, III, and IV.

[0162] In another preferred embodiment, the anti-BK virus antibody molecules or binding fragments thereof do not bind to JC virus VP1. Increased specificity is manifested by the absence of binding to the closely related JC virus VP1. Increased specificity is considered as better safety due to lower risk for off target reactivity.

[0163] As mentioned above, the present disclosure considers anti-BK virus antibody molecules or binding fragments thereof. A full-length antibody includes a constant domain and a variable domain. The constant region need not be present in an antigen-binding fragment of an antibody.

[0164] Binding fragments may thus include portions of an intact full-length antibody, such as an antigen binding or variable region of the complete antibody. Examples of antibody fragments include Fab, F(ab′)2, Id and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); multispecific antibody fragments such as bispecific, trispecific, and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies); minibodies; chelating recombinant antibodies; tribodies or bibodies; intrabodies; nanobodies: small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins; camelized antibodies; VHH containing antibodies; and any other polypeptides formed from antibody fragments. The skilled person is aware that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.

[0165] Disclosed herein are polypeptides having the sequences specified, or sequences substantially identical or similar thereto, e.g. sequences having at least about 85%, 90%, 95%, or 99% sequence identity to the sequence specified.

[0166] The determination of percent identity between two sequences is preferably accomplished using the mathematical algorithm of Karlin and Altschul (1993) Proc. Natl. Acad. Sci USA 90: 5873-5877. Such an algorithm is incorporated into the BLASTp (Protein BLAST) program of Altschul et al. (1990) J. Mol. Biol. 215: 403-410 available at NCBI (https://blast.ncbi.nlm.nih.gov/). The determination of percent identity may be performed with the standard parameters of the BLASTp program. For the general parameters, the “Max Target Sequences” box may be set to 100, the “Short queries” box may be ticked, the “Expect threshold” box may be set to 10, the “Word Size” box may be set to “3” and the “Max matches in a query range” may be set to “0”. For the scoring parameters the “Matrix” box may be set to “BLOSUM62”, the “Gap Costs” Box may be set to “Existence: 11 Extension:1”, the “Compositional adjustments” box may be set to “Conditional compositional score matrix adjustment”. For the Filters and Masking parameters the “Low complexity regions” box may not be ticked, the “Mask for lookup table only” box may not be ticked and the “Mask lower case letters” box may not be ticked.

[0167] According to the disclosure, a “conservative amino acid substitution” is an amino acid substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0168] As mentioned, the disclosure also relates in some embodiments to a nucleic acid encoding antibody molecules or binding fragments thereof, vectors comprising such nucleic acids and host cells comprising such nucleic acids or vectors.

[0169] The antibody molecules or binding fragments thereof may be encoded by a single nucleic acid (e.g., a single nucleic acid comprising nucleotide sequences that encode the light and heavy chain polypeptides of the antibody), or by two or more separate nucleic acids, each of which encode a different part of the antibody molecule or antibody fragment. The nucleic acids may be DNA, cDNA, RNA and the like.

[0170] The nucleic acids described herein can be inserted into vectors. A “vector” is any molecule or composition that has the ability to carry a nucleic acid sequence into a suitable cell where synthesis of the encoded polypeptide can take place.

[0171] The present disclosure in some aspects further provides a host cell (e.g., an isolated or purified cell) comprising a nucleic acid or vector of the invention. The host cell can be any type of cell capable of being transformed with the nucleic acid or vector of the invention so as to produce a polypeptide encoded thereby.

[0172] The anti-BK virus antibody molecules or anti-BK virus binding fragments thereof can be formulated in compositions, especially pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of an antibody or binding fragment thereof in admixture with a pharmaceutically acceptable carrier, excipient or stabilizer.

[0173] Further, the anti-BK virus antibody molecules or anti-BK virus binding fragments thereof and the pharmaceutical compositions as described herein can be administered in methods of treating or preventing a BK virus infection and/or a BK virus associated disorder.

[0174] Preferred embodiments of aspects B1 to B9 of the present invention relate to: 1. An anti-BK virus antibody molecule or an anti-BK virus binding fragment thereof comprising:

[0175] (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 34 or a sequence having one or two amino acid substitutions, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 35 or a sequence having one or two amino acid substitutions, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 36 or a sequence having one or two amino acid substitutions; and

[0176] a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 37 or a sequence having one or two amino acid substitutions, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 38 or a sequence having one or two amino acid substitutions, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 39 or a sequence having one or two amino acid substitutions; or

[0177] (ii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 34 or a sequence having one or two amino acid substitutions, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 44 or a sequence having one or two amino acid substitutions, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 36 or a sequence having one or two amino acid substitutions; and

[0178] a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 37 or a sequence having one or two amino acid substitutions, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 38 or a sequence having one or two amino acid substitutions, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 39 or a sequence having one or two amino acid substitutions; or

[0179] (iii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 34 or a sequence having one or two amino acid substitutions, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 44 or a sequence having one or two amino acid substitutions, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 36 or a sequence having one or two amino acid substitutions; and

[0180] a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 37 or a sequence having one or two amino acid substitutions, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 38 or a sequence having one or two amino acid substitutions, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 48 SEQ ID NO: 48 or a sequence having one or two amino acid substitutions.

[0181] 2. The antibody molecule or binding fragment thereof of item 1, comprising:

[0182] (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 34, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 35, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 36; and

[0183] a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 37, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 38, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 39; or

[0184] (ii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 34, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 44, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 36; and

[0185] a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 37, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 38, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 39; or

[0186] (iii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 34, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 44, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 36; and

[0187] a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 37, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 38, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 48 SEQ ID NO: 48.

[0188] 3. The antibody molecule or binding fragment thereof of items 1 or 2, comprising

[0189] (i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 40, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 40, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 41, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 41; or

[0190] (ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 45, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 45, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 41, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 41; or

[0191] (iii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 49, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 49, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 50, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 50.

[0192] 4. The antibody molecule or binding fragment thereof of any one of items 1-3, comprising

[0193] (i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 40, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 41; or

[0194] (ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 45, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 41; or

[0195] (iii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 49, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 50.

[0196] 5. The antibody molecule or binding fragment thereof of any one of items 1-4, comprising one or more one or more (e.g., 2, 3, 4, 5, 6, 7, 8 or 9) of the following properties:

[0197] (i) binds to BK virus serotype I VP1 with a EC50 of less than about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.19 nM, 0.18 nM, 0.17 nM, 0.16 nM, 0.15 nM, 0.14 nM, 0.13 nM, 0.12 nM, 0.11 nM, 0.10 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM, 0.03 nM or 0.02 nM e.g., when the antibody molecule or binding fragment thereof is tested as a bivalent molecule using ELISA, e.g., as described in Example 2;

[0198] (ii) binds to BK virus serotype VP1 with a EC50 of less than about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.19 nM, 0.18 nM, 0.17 nM, 0.16 nM, 0.15 nM, 0.14 nM, 0.13 nM, 0.12 nM, 0.11 nM, 0.10 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM, 0.03 nM or 0.02 nM e.g., when the antibody molecule or binding fragment thereof is tested as a bivalent molecule using ELISA, e.g., as described in Example 2;

[0199] (iii) binds to BK virus serotype III VP1 with a EC50 of less than about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.19 nM, 0.18 nM 0.17 nM, 0.16 nM, 0.15 nM, 0.14 nM, 0.13 nM, 0.12 nM, 0.11 nM, 0.10 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM, 0.03 nM or 0.02 nM e.g., when the antibody molecule or binding fragment thereof is tested as a bivalent molecule using ELISA, e.g., as described in Example 2;

[0200] (iv) binds to BK virus serotype IV VP1 with a EC50 of less than about 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.19 nM, 0.18 nM, 0.17 nM, 0.16 nM, 0.15 nM, 0.14 nM, 0.13 nM, 0.12 nM, 0.11 nM, 0.10 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM, 0.03 nM or 0.02 nM e.g., when the antibody molecule or binding fragment thereof is tested as a bivalent molecule using ELISA, e.g., as described in Example 2;

[0201] (v) does not bind to JC virus VP1;

[0202] (vi) neutralizes BK virus serotype I;

[0203] (vii) neutralizes BK virus serotype 1l;

[0204] (viii) neutralizes BK virus serotype III;

[0205] (ix) neutralizes BK virus serotype IV.

[0206] 6. An antibody molecule or a binding fragment thereof that competes for binding to BK virus serotype I VP1, BK virus serotype VP1, BK virus serotype III VP1, and/or BK virus serotype IV VP1 with the antibody molecule or binding fragment thereof of any one of items 1-5.

[0207] 7. A pharmaceutical composition comprising the antibody molecule or binding fragment thereof of any one of items 1-6 and a pharmaceutically acceptable carrier, excipient or stabilizer.

[0208] 8. An antibody molecule or binding fragment thereof according to any one of items 1-6 or a pharmaceutical composition according to item 7 for use in the treatment or prevention of a BK virus infection and/or a BK virus associated disorder.

[0209] 9. A nucleic acid encoding the antibody heavy and/or light chain variable region of the antibody molecule or binding fragment thereof of any one of items 1-6.

[0210] 10. An expression vector comprising the nucleic acid of item 9.

[0211] 11. A host cell comprising the nucleic acid of item 9 or the expression vector of item 10.

[0212] 12. A method of producing an antibody molecule, the method comprising culturing the host cell of item 11 under conditions suitable for gene expression.

[0213] 13. A diagnostic composition comprising the antibody molecule or binding fragment thereof of any one of items 1-6.

EXAMPLES

Introductory Comments

[0214] The amino acid sequences of the VP1 protein constructs used in the following examples are summarized in Table 1 below.

TABLE-US-00001 TABLE 1 Amino acid sequences of VP1 protein constructs BKV serotype I SEQ ID VP1-I VP1- GGVEVLEVKTGVDAITEVECFLNPEMGDPD NO: 1 Pentamer ENLRGFSLKLSAENDFSSDSPERKMLPCYS TARIPLPNLNEDLTCGNLLMWEAVTVQTEVI GITSMLNLHAGSQKVHEHGGGKPIQGSNFH FFAVGGDPLEMQGVLMNYRTKYPDGTITPK NPTAQSQVMNTDHKAYLDKNNAYPVECWV PDPSRNENTRYFGTFTGGENVPPVLHVTNT ATTVLLDEQGVGPLCKADSLYVSAADICGL FTNSSGTQQWRGLARYFKIRLRKRSVKNPY SEQ ID VP1-Ia BK MAPTKRKGECPGAAPKKPKEPVQVPKLLIK NO: 2 pseudovirus GGVEVLEVKTGVDAITEVECFLNPEMGDPD ENLRGFSLKLSAENDFSSDSPERKMLPCYS TARIPLPNLNEDLTCGNLLMWEAVTVQTEVI GITSMLNLHAGSQKVHEHGGGKPIQGSNFH FFAVGGDPLEMQGVLMNYRTKYPDGTITPK NPTAQSQVMNTDHKAYLDKNNAYPVECWV PDPSRNENTRYFGTFTGGENVPPVLHVTNT ATTVLLDEQGVGPLCKADSLYVSAADICGL FTNSSGTQQWRGLARYFKIRLRKRSVKNPY PISFLLSDLINRRTQRVDGQPMYGMESQVE EVRVFDGTERLPGDPDMIRYIDKQGQLQTK ML SEQ ID VP1-Ib BK MAPTKRKGECPGAAPKKPKEPVQVPKLLIK NO: 3 pseudovirus GGVEVLEVKTGLDAITEVECFLNPEMGDPD ENLRGFSLKLSAENDFSSDSPDRKMLPCYS TARIPLPNLNEDLTCGNLLMWEAVTVQTEVI GITSMLNLHAGSQKVHEHGGGKPIQGSNFH FFAVGGDPLEMQGVLMNYRTKYPEGTITPK NPTAQSQVMNTDHKAYLDKNNAYPVECWI PDPSRNENTRYFGTFTGGENVPPVLHVTNT ATTVLLDEQGVGPLCKADSLYVSAADICGL FTNSSGTQQWRGLARYFKIRLRKRSVKNPY PISFLLSDLINRRTQRVDGQPMYGMESQVE EVRVFDGTERLPGDPDMIRYIDKQGQLQTK ML BKV serotype II SEQ ID VP1-II VP1- GGVEVLEVKTGVDAITEVECFLNPEMGDPD NO: 4 pentamer DNLRGYSLKLTAENAFDSDSPDKKMLPCYS TARIPLPNLNEDLTCGNLLMWEAVTVKTEV IGITSMLNLHAGSQKVHENGGGKPVQGSNF HFFAVGGDPLEMQGVLMNYRTKYPQGTIT PKNPTAQSQVMNTDHKAYLDKNNAYPVEC WIPDPSRNENTRYFGTYTGGENVPPVLHVT NTATTVLLDEQGVGPLCKADSLYVSAADIC GLFTNSSGTQQWRGLARYFKIRLRKRSVKN PY SEQ ID VP1-II BK MAPTKRKGECPGAAPKKPKEPVQVPKLLIK NO: 5 pseudovirus GGVEVLEVKTGVDAITEVECFLNPEMGDPD DNLRGYSLKLTAENAFDSDSPDKKMLPCYS TARIPLPNLNEDLTCGNLLMWEAVTVKTEV IGITSMLNLHAGSQKVHENGGGKPVQGSNF HFFAVGGDPLEMQGVLMNYRTKYPQGTIT PKNPTAQSQVMNTDHKAYLDKNNAYPVEC WIPDPSRNENTRYFGTYTGGENVPPVLHVT NTATTVLLDEQGVGPLCKADSLYVSAADIC GLFTNSSGTQQWRGLARYFKIRLRKRSVKN PYPISFLLSDLINRRTQRVDGQPMYGMESQ VEEVRVFDGTEQLPGDPDMIRYIDRQGQLQ TKMV BKV serotype III SEQ ID VP1-III VP1- MAPTKRKGECPGAAPKKPKEPVQVPKLLIK NO: 6 pentamer GGVEVLEVKTGVDAITEVECFLNPEMGDPD DNLRGYSQHLSAENAFESDSPDRKMLPCY STARIPLPNLNEDLTCGNLLMWEAVTVKTE VIGITSMLNLHAGSQKVHENGGGKPVQGSN FHFFAVGGDPLEMQGVLMNYRTKYPQGTIT PKNPTAQSQVMNTDHKAYLDKNNAYPVEC WIPDPSRNENTRYFGTYTGGENVPPVLHVT NTATTVLLDEQGVGPLCKADSLYVSAADIC GLFTNSSGTQQWRGLARYFKIRLRKRSVKN PYPISFLLSDLINRRTQKVDGQPMYGMESQ VEEVRVFDGTEQLPGDPDMIRYIDRQGQLQ TKMV SEQ ID VP1-III BK MAPTKRKGECPGAAPKKPKEPVQVPKLLIK NO: 7 pseudovir GGVEVLEVKTGVDAITEVECFLNPEMGDPD US DNLRGYSQHLSAENAFESDSPDRKMLPCY STARIPLPNLNEDLTCGNLLMWEAVTVKTE VIGITSMLNLHAGSQKVHENGGGKPVQGSN FHFFAVGGDPLEMQGVLMNYRTKYPQGTIT PKNPTAQSQVMNTDHKAYLDKNNAYPVEC WIPDPSRNENTRYFGTYTGGENVPPVLHVT NTATTVLLDEQGVGPLCKADSLYVSAADIC GLFTNSSGTQQWRGLARYFKIRLRKRSVKN PYPISFLLSDLINRRTQRVDGQPMYGMESQ VEEVRVFDGTEQLPGDPDMIRYIDRQGQLQ TKMV BKV serotype IV SEQ ID VP1-IV VP1- GGVEVLEVKTGVDAITEVECFLNPEMGDPD NO: 8 Pentamer NDLRGYSLRLTAETAFDSDSPDRKMLPCYS TARIPLPNLNEDLTCGNLLMWEAVTVKTEVI GITSMLNLHAGSQKVHENGGGKPIQGSNFH FFAVGGDPLEMQGVLMNYRTKYPEGTVTP KNPTAQSQVMNTDHKAYLDKNNAYPVECW IPDPSRNENTRYFGTYTGGENVPPVLHVTN TATTVLLDEQGVGPLCKADSLYVSAADICGL FTNSSGTQQWRGLPRYFKIRMRKRSVKNP Y SEQ ID VP1- BK MAPTKRKGECPGAAPKKPKEPVQVPKLLIK NO: 9 IVc pseudovirus GGVEVLEVKTGVDAITEVECFLNPEMGDPD NDLRGYSLRLTAETAFDSDSPDRKMLPCYS TARIPLPNLNEDLTCGNLLMWEAVTVKTEVI GITSMLNLHAGSQKVHENGGGKPIQGSNFH FFAVGGDPLEMQGVLMNYRTKYPEGTVTP KNPTAQSQVMNTDHKAYLDKNNAYPVECW IPDPSKNENTRYFGTYTGGENVPPVLHVTN TATTVLLDEQGVGPLCKADSLYVSAADICGL FTNSSGTQQWRGLPRYFKIRLRKRSVKNPY PISFLLSDLINRRTQRVDGQPMYGMESQVE EVRVFDGTEQLPGDPDMIRYIDRQGQLQTK MV JCV SEQ ID VP1 VP1- GGVEVLEVKTGVDSITEVECFLTPEMGDPD NO: 10 Pentamer EHLRGFSKSISISDTFESDSPNRDMLPCYSV ARIPLPNLNEDLTCGNILMWEAVTLKTEVIG VTSLMNVHSNGQATHDNGAGKPVQGTSFH FFSVGGEALELQGVLFNYRTKYPDGTIFPK NATVQSQVMNTEHKAYLDKNKAYPVECWV PDPTRNENTRYFGTLTGGENVPPVLHITNT ATTVLLDEFGVGPLCKGDNLYLSAVDVCGM FTNRSGSQQWRGLSRYFKVQLRKRRVKNP Y

Comparative Antibodies

[0215] P8D11 (WO 2017/046676) was cloned as described for the other antibodies. VH and VL of P8D11 as described in WO 2017/046676 was fused to the identical constant domains of IgG as described below. Amino acid sequences for comparative antibody P8D11 are summarized in Table 2 below.

[0216] Negative control 24C3 is an antibody derived from healthy humans against Tetanus toxoid. The variable fragments were fused to the identical constant domains of IgG as described below.

TABLE-US-00002 TABLE 2 Amino acid sequences for comparative antibody P8D11 (WO 2017/046676) P8D11 (WO 2017/046676) SEQ ID VHCDR1 NYWMT NO: 11 (Kabat) SEQ ID VHCDR2 NIKKDGSEKYYVDSVRG NO: 12 (Kabat) SEQ ID VHCDR3 VRSGRYFALDD NO: 13 (Kabat) SEQ ID VLCDR1 GGDNIGSRPVH NO: 14 (Kabat) SEQ ID VLCDR2 DDSNRPS NO: 15 (Kabat) SEQ ID VLCDR3 QVWSSSTDHP NO: 16 (Kabat) SEQ ID VH QVQLVESGGTLVQPGGSLRLSCAASGFTFNNYWMTWV NO: 17 RQAPGKGLEWVANIKKDGSEKYYVDSVRGRFTISRDN AKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWG QGTLVTVSS SEQ ID VL QSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWYQQ NO: 18 KPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTI SRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVL SEQ ID Full length QVQLVESGGTLVQPGGSLRLSCAASGFTFNNYWMTWV NO: 19 heavy RQAPGKGLEWVANIKKDGSEKYYVDSVRGRFTISRDN chain AKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID Full length QSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWYQQK NO: 20 light chain PGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISR VEAGDEADYYCQVWSSSTDHPFGGGTKVTVLGQPKAAP SVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKAD SSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSH RSYSCQVTH EGSTVEKTVAPTECS

Antibody Discovery

Example 1

[0217] Peripheral blood memory B cells from healthy human donors or kidney transplant recipients were used to prepare antibody repertoire expression libraries by cloning the immunoglobulin light chain and heavy chain variable regions into an expression cassette providing the human immunoglobulin constant heavy region combined with a transmembrane domain derived from human CD8 to allow for mammalian cell display of the antibodies. Screening of the antibody libraries was performed after transduction of the library in HEK 293T cells by antigen-specific sorting using fluorescently labelled VP1-pentamers of BK-Virus.

[0218] This sort yielded BK-Virus-specific-antibody-expressing HEK cell clones which were further propagated to upscale antibody production for downstream analysis of antibody properties such as additional binding assays in ELISA or BK-virus neutralization. The neutralizing capacity of the antibodies was tested using BK pseudoviruses (BK-PsV) carrying a luciferase expressing reporter plasmid and wild type BKV. BK-virus-specific antibodies with high affinity and virus neutralizing capacity were then sub-cloned into expression vectors for soluble antibody expression and expressed after transient transfection in HEK 293F or CHO cells. Antibodies were then purified over protein G or Protein A for characterization in the various assays. Amino acid sequences relating to identified antibody 319C07 are summarized in Table 3 below. In addition, variants were prepared and the corresponding amino acid sequences are also summarized in Table 3 below. Amino acid sequences relating to identified antibody 336F07 are summarized in Table 4 below. In addition, variants were prepared and the corresponding amino acid sequences are also summarized in Table 4 below.

TABLE-US-00003 TABLE 3 Amino acid sequences for anti-BK virus antibodies 319C07 and 319C07-var1. 319C07 SEQ ID VHCDR1 AYYWT NO: 21 (Kabat) SEQ ID VHCDR2 EINHRGYTNYNPSLRG NO: 22 SEQ ID VHCDR3 LRSTSGWHDYFDY NO: 23 (Kabat) SEQ ID VLCDR1 RASQSVSSSYLA NO: 24 (Kabat) SEQ ID VLCDR2 GASSRAT NO: 25 (Kabat) SEQ ID VLCDR3 LQYGSSPLT NO: 26 (Kabat) SEQ ID VH QVQLQQWGAGLLKPSETLSLTCAVYRGSFSAYYWTWF NO: 27 RQPPGKGLEWIGEINHRGYTNYNPSLRGRVSISVDTS KKQFSLKLRSVNAADTAVYYCATLRSTSGWHDYFDYW GQGTLVTVSS SEQ ID VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ NO: 28 TPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR LEPEDFVVYFCLQYGSSPLTFGPGTKVDIK SEQ ID Full length QVQLQQWGAGLLKPSETLSLTCAVYRGSFSAYYWTWFR NO: 29 heavy QPPGKGLEWIGEINHRGYTNYNPSLRGRVSISVDTSKK chain QFSLKLRSVNAADTAVYYCATLRSTSGWHDYFDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID Full length EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ NO: 30 light chain TPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR LEPEDFVVYFCLQYGSSPLTFGPGTKVDIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC 319C07-var1 SEQ ID VHCDR1 AYYWT NO: 21 (Kabat) SEQ ID VHCDR2 EINHRGYTNYNPSLRG NO: 22 SEQ ID VHCDR3 LRSTSGWHDYFDY NO: 23 (Kabat) SEQ ID VLCDR1 RASQSVSSSYLA NO: 24 (Kabat) SEQ ID VLCDR2 GASSRAT NO: 25 (Kabat) SEQ ID VLCDR3 LQYGSSPLT NO: 26 (Kabat) SEQ ID VH QVQLQQWGAGLLKPSETLSLTCAVYRGSFSAYYWTWF NO: 27 RQPPGKGLEWIGEINHRGYTNYNPSLRGRVSISVDTS KKQFSLKLRSVNAADTAVYYCATLRSTSGWHDYFDYW GQGTLVTVSS SEQ ID VL EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ NO: 31 KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR LEPEDFAVYFCLQYGSSPLTFGPGTKVDIK SEQ ID Full length QVQLQQWGAGLLKPSETLSLTCAVYRGSFSAYYWTWFR NO: 32 heavy QPPGKGLEWIGEINHRGYTNYNPSLRGRVSISVDTSKK chain QFSLKLRSVNAADTAVYYCATLRSTSGWHDYFDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID Full length EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ NO: 33 light chain KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR LEPEDFAVYFCLQYGSSPLTFGPGTKVDIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC

TABLE-US-00004 TABLE 4 Amino acid sequences for anti-BK virus antibodies 336F07, 336F07- var1 and 336FO7-var4. 336F07 SEQ ID VHCDR1 LYAMN NO: 34 (Kabat) SEQ ID VHCDR2 LISGSGTATYYADSVTG NO: 35 (Kabat) SEQ ID VHCDR3 TYPTWGGVVIGAIDV NO: 36 (Kabat) SEQ ID VLCDR1 RASQSIQRWLA NO: 37 (Kabat) SEQ ID VLCDR2 DASTLES NO: 38 (Kabat) SEQ ID VLCDR3 QQYNGHAST NO: 39 (Kabat) SEQ ID VH EEPLLESGGGLVQPGGSLRLSCAASGFTFRLYAMNWVR NO: 40 QAPGKGLEWVSLISGSGTATYYADSVTGRFSISRDNYK NRVYLQMDSLRADDTATYYCAKTYPTWGGVVIGAIDVW GQGTTVTVSS SEQ ID VL DIQMTQSPSTLSASVGDRVTITCRASQSIQRWLAWHQQ NO: 41 KPGRAPKVLIHDASTLESGVPSRFSGSGSGTEFTLTIS SLQPDDFATYYCQQYNGHASTFGPGTKVDIK SEQ ID Full length EEPLLESGGGLVQPGGSLRLSCAASGFTFRLYAMNWVR NO: 42 heavy QAPGKGLEWVSLISGSGTATYYADSVTGRFSISRDNYK chain NRVYLQMDSLRADDTATYYCAKTYPTWGGVVIGAIDVW GQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID Full length DIQMTQSPSTLSASVGDRVTITCRASQSIQRWLAWHQQ NO: 43 light chain KPGRAPKVLIHDASTLESGVPSRFSGSGSGTEFTLTIS SLQPDDFATYYCQQYNGHASTFGPGTKVDIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC 336F07-var1 SEQ ID VHCDR1 LYAMN NO: 34 (Kabat) SEQ ID VHCDR2 LISGSGTATYYADSVKG NO: 44 (Kabat) SEQ ID VHCDR3 TYPTWGGVVIGAIDV NO: 36 (Kabat) SEQ ID VLCDR1 RASQSIQRWLA NO: 37 (Kabat) SEQ ID VLCDR2 DASTLES NO: 38 (Kabat) SEQ ID VLCDR3 QQYNGHAST NO: 39 (Kabat) SEQ ID VH EEPLLESGGGLVQPGGSLRLSCAASGFTFRLYAMNWVR NO: 45 QAPGKGLEWVSLISGSGTATYYADSVKGRFSISRDNSK NRVYLQMSSLRADDTATYYCAKTYPTWGGVVIGAIDVW GQGTTVTVSS SEQ ID VL DIQMTQSPSTLSASVGDRVTITCRASQSIQRWLAWHQQ NO: 41 KPGRAPKVLIHDASTLESGVPSRFSGSGSGTEFTLTIS SLQPDDFATYYCQQYNGHASTFGPGTKVDIK SEQ ID Full length EEPLLESGGGLVQPGGSLRLSCAASGFTFRLYAMNWVR NO: 46 heavy QAPGKGLEWVSLISGSGTATYYADSVKGRFSISRDNSK chain NRVYLQMSSLRADDTATYYCAKTYPTWGGVVIGAIDVW GQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRWVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID Full length DIQMTQSPSTLSASVGDRVTITCRASQSIQRWLAWHQQ NO: 47 light chain KPGRAPKVLIHDASTLESGVPSRFSGSGSGTEFTLTIS SLQPDDFATYYCQQYNGHASTFGPGTKVDIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSFNRGEC 336F07-var4 SEQ ID (Kabat) LYAMN NO: 34 SEQ ID VHCDR2 LISGSGTATYYADSVKG NO: 44 (Kabat) SEQ ID VHCDR3 TYPTWGGVVIGAIDV NO: 36 (Kabat) SEQ ID VLCDR1 RASQSIQRWLA NO: 37 (Kabat) SEQ ID VLCDR2 DASTLES SEQ ID (Kabat) NO: 48 SEQ ID NO: 48 NO: 38 VLCDR3 QQYSGHAST (Kabat) SEQ ID VH EEPLLESGGGLVQPGGSLRLSCAASGFTFRLYAMNWVR NO: 49 QAPGKGLEWVSLISGSGTATYYADSVKGRFTISRDNSK NRVYLQMSSLRADDTAVYYCAKTYPTWGGVVIGAIDVW GQGTTVTVSS SEQ ID VL DIQMTQSPSTLSASVGDRVTITCRASQSIQRWLAWHQQ NO: 50 KPGKAPKLLIHDASTLESGVPSRFSGSGSGTEFTLTIS SLQPDDFATYYCQQYSGHASTFGPGTKVDIK SEQ ID Full length EEPLLESGGGLVQPGGSLRLSCAASGFTFRLYAMNWVR NO: 51 heavy QAPGKGLEWVSLISGSGTATYYADSVKGRFTISRDNSK chain NRVYLQMSSLRADDTAVYYCAKTYPTWGGVVIGAIDVW GQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID Full length DIQMTQSPSTLSASVGDRVTITCRASQSIQRWLAWHQQ NO: 52 light chain KPGKAPKLLIHDASTLESGVPSRFSGSGSGTEFTLTIS SLQPDDFATYYCQQYSGHASTFGPGTKVDIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQCEVTHQGLSSPVTKSFNRGEC

Assays

Example 2—Binding to VP1-Pentamer in ELISA

Material and Methods

[0219] The binding of anti-BK virus antibodies to BKV-VP1 pentamers was analyzed by ELISA. Briefly, Costar® 96 well Assay Plates, half area high binding plates (Corning Inc. #3690) were coated with 30 μl/well of 1 μg/ml BKV-VP1 pentamers overnight at 4° C. Subsequently, the plate was blocked using 5% skim milk powder (Rapilait, Migros #7610200017598) diluted in PBS. Antibodies were serially diluted in PBS with 0.5% skim milk powder and added to the antigen-coated plates for 1.5 h. Then, plates were washed with PBS 0.05% Tween20 (AppliChem, A4974) and incubated with enzyme-labelled secondary antibody (HRP-conjugated goat anti-human IgG, Jackson-Immuno #109-035-098) diluted 1:10′000 in PBS with 0.5% skim milk powder for 45 min. Plates were washed three times with PBS containing 0.05% Tween 20. The reaction was developed using 30 μl/well TMB liquid substrate (Sigma-Aldrich, #T0440) and stopped with 15 μl/well H.sub.2SO.sub.4. Absorbance was detected at 450 nm (Tecan, CM INFINITE MONO 200). Data were fitted and apparent EC50 ELISA values (EC50.sub.E) were determined by three-parameter analysis in GraphPad Prism (GraphPad Software).

Results

[0220] The antibody 319C07 showed strong and selective binding to all BKV-VP1 serotypes (FIG. 1, EC50.sub.E values below). Compared to comparative antibody P8D11, antibody 319C07 showed higher affinity for serotype 1, and IV and showed a comparable affinity on BKV-VP1-serotype III.

TABLE-US-00005 EC50.sub.E (nM) VP1-I VP1-II VP1-III VP1-IV 319C07 0.05 0.06 0.06 0.06 P8D11 0.14 0.19 0.07 0.12

[0221] Also the antibody 336F07 showed strong and selective binding to all BKV-VP1 serotypes (FIG. 1, EC50.sub.E values below). Compared to comparative antibody P8D11, antibody 336F07 showed higher affinity on all four serotypes.

TABLE-US-00006 EC50.sub.E (nM) VP1-I VP1-II VP1-III VP1-IV 336F07 0.07 0.03 0.02 0.03 P8D11 0.14 0.19 0.07 0.12

Example 3—Neutralization of BK-Pseudovirus by Anti-BK Virus Antibodies

Material and Methods

[0222] BK Pseudovirus (BK-PsV) carrying the NanoLuc reporter gene was produced as described (Pastrana et al, J Virol, 2013 September; 87(18):10105-13). Five different genotypes were produced: BKV-la (BK-D; JF894228), BKV-Ib2 (PittVR2; DQ989796) BKV-II (Q85238; CAA79596), BKV-III (Q0PDA6; BAF03017) and BKV-IVc2 (A-66H; AB369093). VP1 was purified over Agarose gel beads as described (Buck et al, J Virol, 2008 June; 82(11):5190-7 and Buck et al, Curr Protoc Cell Biol, 2007 December; Chapter 26; 26.21). Infectious virus titer was determined on 293TT cells. Different dilutions of the BK-PsV were tested in a 96 well plate with and without inhibitor. The dilution selected for further assays resulted in a high luminescence signal in non-inhibited cells.

[0223] 20′000 cells (293TT) were seeded in a 96 well plate using DMEM containing 9% FBS, HEPES and Penicillin/Streptavidin. After a 5 h incubation, antibodies in various concentrations and a fix amount of BK-Pseudovirus was added to each well and the plate was incubated at 37 C, 5% CO2. After 3 days of incubation luciferase activity in the supernatant fluid was measured using the NanoGlo™ assay reagent (Promega, #N1130).

[0224] 40 ul of cell culture or virus-cell-antibody-co-culture-supernatant was transferred into white bottom 96 well plates, 40 ul of NanoGlo™ substrate was added and incubated for 2 minutes before determination of luciferase activity using a luminescence reader (BioTek Synergy). Data were plotted on a Signal vs antibody concentration curve. IC50 values were determined by GraphPad Prism using non-linear regression (curve fit) and the formula “log(inhibitor) vs normalized response (variable slope)” (GraphPad Software).

Results

[0225] 319C07 and the variant 319C07-var1 show strong inhibition of BK-Pseudovirus from all serotypes. 319C07 outperforms P8D11 significantly (FIG. 2, IC50 values below).

TABLE-US-00007 IC50 (nM) Ia Ib II III IV 319C07 0.007 0.007 0.010 0.058 0.032 P8D11 0.391 0.392 0.565 0.176 2.906

[0226] Also antibody 336F07 and the variants 336F07-var1 and 336F07-var4 show strong inhibition of BK-Pseudovirus from all serotypes. 336F07 outperforms P8D11 significantly (FIG. 2, IC50 values below).

TABLE-US-00008 IC50 (nM) Ia Ib II III IV 336F07 0.094 0.103 0.020 0.019 0.018 P8D11 0.391 0.392 0.565 0.176 2.906

Example 4—Long-Term Virus Neutralization by Anti-BK Virus Antibodies

Material and Methods

[0227] To address long-term virus neutralization by anti-BK virus antibodies in vitro, repetitive cycles of co-cultures of human primary renal proximal tubular epithelial cells (HPRTEC), wild type BK virus strain I (ATCC® VR-837™) and anti-BK virus antibodies were used. At the start of the study, anti-BK virus antibodies were added at three distinct concentrations corresponding to their EC95; EC50 and EC5 viral inhibition potency to cell-virus co-cultures for 1 week. After this period virus was harvested from the cells and remaining supernatant by 3 freeze thaw cycles. 10 ul of this virus extract was then added to freshly seeded HRPTEC cells in the presence of antibodies at the various concentrations. After 2 weeks of inoculation virus load was again quantified and virus extracts were generated to be used in the next infection cycle. This procedure was repeated 3 times resulting in a total of 8 weeks of co-culture.

[0228] The assay was performed in triplica in 96 well flat bottom cell culture plates. Quantification of viral load in the culture supernatant was performed by harvesting 15 μl of media which was then heat-inactivated at 95° C. for 10 min and used for qPCR with primers 5′-GGATGGGCAGCCTATGTATG-3′ (SEQ ID NO: 53), and 5′-TCATATCTGGGTCCCCTGGA-3′ (SEQ ID NO: 54) and a TaqMan™ probe FAM-AGGGTGTTTGATGGCACAGA-TAMRA (SEQ ID NO: 55). PCR was performed using PerfeCTa qPCR ToughMix (Quantabio, #95140) with following conditions: 95° C. for 8 min and 40 cycles of 95° C. for 10 sec and 60° C. for 60 sec.

Results

[0229] Antibody 319C07 shows a more complete neutralization of the virus compared to P8D11. This becomes most apparent when looking at the last infection-neutralization cycle after 8 weeks where at concentrations corresponding to EC95 and EC50 no virus could be detected anymore whereas P8D11 shows measurable virus loads in both EC95 and EC50. (FIG. 3, P8D11 is labelled with “BM2” in this figure).

[0230] Also antibody 336F07 shows a more complete neutralization of the virus compared to P8D11. This becomes most apparent when looking at the last infection-neutralization cycle after 8 weeks (FIG. 3, P8D11 is labelled with “BM2” in this figure).

Example 5—Anti-BK Virus Antibodies Bind to a Conformational Epitope

Material and Methods

[0231] In order to determine whether the anti-BK virus antibodies are binding to a conformational epitope, dot blots of VP1 in native state and in denatured state were performed. BKV-VP1 pentamers of serotypes I, II, III and IV were spotted to a nitrocellulose membrane either in their native form or after chemical and thermal denaturation using Tris buffer containing SDS and p-Mercaptoethanol and heating at 85° C. for 5 min. Both membranes were incubated with the anti-BK virus antibodies and their binding was revealed using HRP-conjugated secondary antibodies directed against human Fc. Detection was done using a colorimetric substrate (Sigma Fast DAB).

Results

[0232] Antibody 319C07 and antibody 336F07 show selective binding to a conformational epitope (FIG. 4). Due to absence of staining of denatured antigen, binding to a linear epitope can be excluded. Commercially available control antibody (Ab53977, Abcam, rabbit-IgG) known to recognize a linear epitope, detected both the denatured and non-denatured VP1.

Example 6—Binding to Mutations of BKV-VP1-Pentamer and to JCV-VP1 Pentamer in ELISA

Material and Methods

[0233] The VP1-Serotype Ib wild type sequence was used as the basis for the introduction of mutations at various positions. Likewise, VP1 of the JC virus was used. The binding of anti-BK virus antibodies to wild type and variant VP1 pentamers was analyzed by ELISA. Briefly, Costar® Assay Plate 96 well, half area high binding plates (Corning Inc. #3690) were coated with 30 μl/well of 1 μg/ml BKV-VP1 pentamer variants overnight at 4° C. After 16 h, non-specific binding was blocked using 5% skim milk powder (Rapilait, Migros #7610200017598) diluted in PBS. Antibodies were serially diluted from 67 nM down to 0.02 nM in PBS containing 0.5% skim milk powder and incubated on the antigen-coated plates for 1.5 h. Plates were then washed three times with PBS 0.05% Tween20 (AppliChem, A4974) and then incubated with secondary antibody (HRP-conjugated goat anti-human IgG, Jackson-Immuno #109-035-098) diluted 1:10′000 in PBS with 0.5% skim milk powder for 45 min. HRP activity of the bound secondary antibodies was revealed using 30 μl/well TMB liquid substrate (Sigma-Aldrich, #T0440). The reaction was stopped after 2.5 min by addition of 15 μl/well 1M H2SO4. Absorbance was detected at 450 nm (Tecan, CM INFINITE MONO 200). Data were plotted and EC50 values were determined by three-parameter analysis in GraphPad Prism (GraphPad Software) and are referred to as EC50ELISA (EC50E).

Results

[0234] Binding to mutant forms of BKV VP1 in comparison to wild type VP1 and to VP1 of the closely related JC polyoma virus was tested for antibody 319C07 in comparison to antibody P8D11. Antibody 319C07 does not bind at all to VP1 of the JC virus whereas antibody P8D11 shows weak but significant binding. If amino acids at position N62, D175 or S275 is mutated to alanine, 319C07 shows a slightly reduced binding affinity. Changing amino acid K172 to alanine does not lower the binding. P8D11 on the other hand, shows reduced binding to the VP1-1-K172A mutant, while binding is not affected to N62A, D175A or S275A mutations. Compared to antibody P8D11, 319C07 shows here a clearly distinct pattern suggesting that it interacts with different amino acids of VP1 compared to P8D11 (FIG. 5).

[0235] Binding to mutant forms of BKV VP1 in comparison to wild type VP1 and to VP1 of the closely related JC polyoma virus was also tested for antibody 336F07 in comparison to antibody P8D11. Antibody 336F07 does not bind at all to VP1 of the JC virus whereas antibody P8D11 shows weak but significant binding. If amino acids at position N62 or E73 is mutated, 336FC07 shows a slightly reduced binding affinity. Changing amino acid K172 to alanine does not lower the binding. P8D11 on the other hand, shows reduced binding to the VP1-I-K172A mutant, while binding is not affected to N62A or E73Q mutations. Compared to antibody P8D11, 336F07 shows here a clearly distinct pattern suggesting that it interacts with different amino acids of VP1 compared to P8D11 (FIG. 5).

Example 7—Inhibition of Virus Spread from Infected HRPTEC Cells

Material and Methods

[0236] Primary Human Renal Proximal Tubule Epithelial Cells (HRPTEC) were infected with BKV (strain 33-1, ATCC® 45024™). After 5 days, cells were gently scratched with a cell scraper and extensively washed with PBS to remove all cell free virus. Cells were then added to wells containing adherent growing HRPTEC and various dilutions of BKV-neutralizing antibody. 8 days after inoculation of cells 10 μl of supernatant fluid was removed from each well and viral load was determined using quantitative PCR using primers 5′-GGATGGGCAGCCTATGTATG-3′ (SEQ ID NO: 53), 5′-TCATATCTGGGTCCCCTGGA-3′ (SEQ ID NO: 54) and probe FAM-5′-AGGGTGTTTGATGGCACAGA-3′-TAMRA (SEQ ID NO: 55) as described (Martelli et al., Viruses, 2018 Aug. 30; 10(9):466).

Results

[0237] Antibody 319C07 is showing around 100 fold superiority over P8D11 for inhibition of BKV spread among HRPTEC; also antibody 336F07 is showing significant superiority over P8D11 for inhibition of BKV spread among HRPTEC (FIG. 6, P8D11 is labelled with “BM2” in this figure).

Example 8—Antibody-Dependent-Cellular-Cytotoxicity (ADCC)

Material and Methods

[0238] HPRTEC seeded in flat bottom 96 well plates either infected with wild type BK virus strain I (ATCC® VR-837™) or left uninfected were used as target cells. As effector cells, engineered Jurkat cells, components of the ADCC Reporter Bioassay G7015 from Promega were used. In this assay, as a surrogate for ADCC activity, Fc-γRIIIa signalling by the effector cells is quantified through a luminescence readout. Anti-BKV or control antibodies in serial dilutions were added at to the HPRTEC culture together with the effector cells and incubated for 6 h prior to developing and measuring the bioluminescence as described by the assay kit manufacturer.

[0239] Results

[0240] 319C7 and 336F07 showed comparable ADCC activity on infected HPRTEC which in turn was comparable to that of P8D11. No ADCC was observed on HPRTEC that were left uninfected with either 319C7 and 336F07 or P8D11 (FIG. 7).

Example 9—Complement-dependent-toxicity

Material and Methods

[0241] HPRTEC seeded in flat bottom 96 well plates either infected with wild type BK virus strain I (ATCC® VR-837™) or left uninfected were used as target cells. Cells were incubated with anti-BKV antibodies at serial dilutions starting with 100 μg/ml and 20% human serum overnight and cell viability was quantified by determining the ratio of living cells using the FSC/SSC criterium in a cytometer.

Results

[0242] 319C7 and 336F07 showed no CDC activity at a concentration of 100 μg/ml on infected HPRTEC and the same observation was made with antibody P8D11 and control antibody Rituximab directed against an irrelevant target on HRPTEC (FIG. 8).